✦ LIBER ✦

Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study

✍ Scribed by Lothar Bergmann; Klaus Fenchel; Eckhart Weidmann; Hans-Martin Enzinger; Bernhard Jahn; Dieter Jonas; Paris S. Mitrou

Publisher: John Wiley and Sons
Year: 1993
Tongue: English
Weight: 852 KB
Volume: 72
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19930901)72:5<1733::aid-cncr2820720537>3.0.co;2-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I study of recombinant human int

A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma

✍ A. Mittelman; M. Huberman; C. Puccio; B. Fallon; J. Tessitore; S. Savona; R. Eyr 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 662 KB

Preclinical data suggest synergy of interleukin-2 (IL-2) combined with alphainterferon (IFN). In addition, toxicities of IL-2 may be decreased by intermittent continuous infusion. The purpose of this trial was to determine the maximum tolerated dose (MTD) of recombinant IL-2 combined with alpha-IFN

Continuous infusion of high-dose 5-fluor

Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A multicenter phase II study

✍ Cornelis J. A. Punt; Jos Th. M. Burghouts; Jelle J. Croles; Peter A. van Liessum 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 499 KB 👁 2 views

Improved tolerability and quality of lif

Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-α-2b : Results of a randomized phase II trial of low-dose versus intermediate-dose interferon-α-2b in patients with metastatic renal cell carcinoma

✍ Nizar M. Tannir; Lorenzo Cohen; Xuemei Wang; Peter Thall; Paul F. Mathew; Eric J 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 2 views

A phase II study of days 1 and 8 cisplat

A phase II study of days 1 and 8 cisplatin and recombinant alpha-2B interferon in advanced non-small cell lung cancer

✍ R. Rosell; J. Carles; I. Moreno; N. Ribelles; V. Solano; A. Barnadas; A. Abad; A 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 660 KB

Interleukin-2, interferon-α, 5-fluoroura

Interleukin-2, interferon-α, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma : A prospective Phase II study: The experience of Rambam and Lin Medical Centers 1996-2000

✍ Eliahu Gez; Raphael Rubinov; Diana Gaitini; Shimon Meretyk; Lael-Anson Best; Ofe 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

## Abstract ## BACKGROUND The current study evaluated the efficacy and toxicity of interleukin‐2 (IL‐2), interferon‐α (IFN‐α), 5‐fluorouracil (5‐FU), and vinblastine (VBL) in the treatment of metastatic renal cell carcinoma (MRCC). ## METHODS Sixty‐two MRCC patients, median age 63 years, receive

Interferon-α-2a with or without 13-cis r

Interferon-α-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma : Results of a randomized Phase II study (European Organization for Research and Treatment of Cancer Study 30951)

✍ Sophie D. Fosså; Gerald H. J. Mickisch; Pieter H. M. De Mulder; Simon Horenblas; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

## Background: In patients with metastatic renal cell carcinoma (mrcc), interferon-alpha (ifn) monotherapy leads to response rates of 5-15%, dependent on the selection of patients. in 1995, preclinical and clinical data indicated an improvement of these results if ifn was combined with 13-cis retin